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Abstract
Background: Lupus nephritis (LN) is a complex chronic autoimmune disease of unknown etiology characterized by
loss of tolerance against several self-antigens. Cytokines are known to be central players in LN pathogenesis. The
Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is one important pathway that
mediates signal transduction of several cytokines. In this study, we examined the pathogenic role of this pathway
and how CP-690,550 treatment influences LN outcome.
Methods: Six-month-old NZB/NZWF1 mice were divided into two different treatment groups: (1) control animals
given vehicle treatment, cyclophosphamide, and mycophenolate mofetil treatment as positive controls of the
therapy and (2) mice treated with CP-690,550, a JAK3 inhibitor. Mice were treated for 12 weeks. We evaluated renal
function, anti-double-stranded DNA (anti-dsDNA) antibody, renal histology changes, kidney complement and
immunoglobulin G (IgG) deposits, T-cell and macrophage infiltration, kidney inflammatory gene expression, and
circulating cytokine changes.
Results: CP-690,550 treatment significantly reduced proteinuria and improved renal function and histological
lesions of the kidney. Compared with vehicle-treated animals, those undergoing CP-690,550 treatment showed
significantly diminished anti-dsDNA antibody and complement component C3 and IgG deposition in glomeruli.
We also observed a significant reduction of T-cell and macrophage infiltration. Kidney gene expression revealed a
reduction in inflammatory cytokines and complement and related macrophage-attracting genes. Circulating
inflammatory cytokines were also reduced with treatment.
Conclusions: On the basis of our results, we conclude that the JAK-STAT pathway is implicated in the progression
of renal inflammation in NZB/WF1 mice and that targeting JAK3 with CP-690,550 is effective in slowing down the
course of experimental LN. Thus, CP-690,550 could become a new therapeutic tool in LN and other autoimmune
diseases.
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Background
Systemic lupus erythematosus (SLE) is a chronic systemic
autoimmune disorder characterized by loss of tolerance
against nuclear autoantigens, anti-double-stranded DNA
(anti-dsDNA) antibody production, immune complex (IC)
deposition, and leukocyte infiltration in many target or-
gans, as well as activated B and T cells [1, 2]. Lupus
nephritis (LN) is an IC glomerulonephritis categorized as
one of the most serious complications of SLE and is also
one of the strongest predictors of a poor prognosis. LN
can lead to severe proteinuria, hypertension, chronic renal
failure, and, finally, end-stage kidney disease.
It is well known that the cytokine milieu is integrally
involved in the pathogenesis of autoimmune diseases
[3, 4]. Multiple cytokines, such as interferons (IFNs),
tumor necrosis factor (TNF)-α interleukin (IL)-6, IL-12,
IL-10, and IL-17, are implicated in the initiation, progres-
sion, and development of LN. Serum levels of several of
them have been found to be elevated in patients with
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active SLE and in murine LN models [5–8], and abnor-
mally high levels are associated with more severe disease
and severity [9, 10]. IL-6 is a proinflammatory cytokine
that plays a central regulatory role in the development,
maturation, survival, and immunoglobulin secretion of
long-lived plasma cells [11]. IL-17 amplifies the immune
response by inducing the local production of chemokines
and cytokines, recruiting neutrophils and monocytes, aug-
menting the production of autoantibodies, and aggravating
the inflammation and damage of target organs [12].
One of the best-understood mechanisms by which cy-
tokines activate signals, thus eliciting specific responses
in target cells, involves enzymes such as Janus kinases
(JAKs) and transcriptional factors such as signal trans-
ducers and activators of transcription (STATs). The JAK-
STAT signaling pathways are used by all type I and type
II cytokine receptors. Following ligation, JAK phosphor-
ylates the cytoplasmic tail of its receptor, which becomes
activated, leading to the recruitment of STATs. After-
ward, STATs translocate into the nucleus, where they
regulate the expression of numerous genes [13]. The
pathological consequences of deregulated JAK/STAT
signaling have been widely documented in many animal
models of chronic inflammatory and autoimmune
diseases as well as cancers [14]. Some polymorphisms of
JAK/STAT genes have also been associated with suscep-
tibility to SLE [15, 16]. This association with severe
immune dysfunction reveals the key role of this pathway
in the induction and regulation of immune responses.
The JAK3 inhibitor CP-690,550 is a drug currently ap-
proved for the treatment of rheumatoid arthritis. It is
currently also being evaluated for the treatment of other
autoimmune diseases, as well as for the prevention of
organ transplant rejection [17, 18]. Very few studies have
assessed this family of drugs in the context of LN. CP-
690,550 is an orally available compound that specifically
binds to the adenosine triphosphate (ATP)-binding
pocket of JAK3, though recent studies have shown that
CP-690,550 is also able to bind to the ATP pocket in both
JAK1 and JAK2 [19, 20]. Therefore, CP-690,550 is currently
categorized as a pan-JAK inhibitor preferentially inhibiting
JAK3 and JAK1, and to a lesser extent JAK2.
In contrast to the relatively ubiquitous expression of
JAK1, JAK2, and Tyk2, JAK3 has a more restricted and
regulated expression. JAK3 is selectively expressed in
hematopoietic cells, natural killer cells, thymocytes, T
and B cells, and myeloid cells, and mutation in this kin-
ase results in a loss of immunological function and in se-
vere combined immunodeficiency [13]. We hypothesized
that blocking the enzymatic activity of JAK3 might also
result in immunosuppression, thereby offering a novel,
attractive, and promising strategy in the treatment of in-
flammatory immune-mediated diseases. Therefore, in
the present study, we examined the effects of blocking
the JAK-STAT pathway on disease progression and renal
lesions in NZB/WF1 mice via in vivo administration of
CP-690,550. We further evaluated whether this blockade
interferes only locally in the progression of LN or also in
downstream mechanisms of SLE development.
Methods
Mice, study design, and follow-up
Five-month-old NZB/WF1 mice (JAX®; Charles River
Laboratories, Barcelona, Spain) were randomly assigned
to four groups. At 6 months of age, treatment was initi-
ated as follows, by group: intraperitoneal cyclophospha-
mide (CYP) 50 mg/kg/10 days (n = 14), subcutaneous
CP-690,550 (CP, XELJANZ® [tofacitinib]; Pfizer, New
York, NY, USA) 48 mg/kg/day (n = 8), oral mycopheno-
late mofetil (MMF, CellCept®; ROCHE FARMA, Madrid,
Spain) 30 mg/kg/daily (n = 8), and subcutaneous PBS
treatment (n = 14) as a control group. Mice were treated
for 12 weeks. Their body weight was determined twice
monthly from the beginning to the end of follow-up.
Mice were placed in metabolic cages to collect 24-h
urine specimens before the onset of treatment, and
monthly thereafter. Blood was obtained from the tail
vein at monthly intervals. Kidneys were processed for
histological and biochemical studies at the end of the
study or at death.
The experiments were carried out in accordance with
current European Union legislation on animal experi-
mentation and were approved by the animal experimen-
tation ethics committee, the University of Barcelona
Institutional Ethics Committee for Animal Research, and
the Animal Experimentation Commission of the Gener-
alitat de Catalunya (Catalonian government). The mice
were housed in a room at constant temperature with a
12-h dark/12-h light cycle, were given free access to
water, and were fed a standard laboratory diet.
Proteinuria, albuminuria, and renal function
Twenty-four-hour urinary protein was determined by
Pyrogallol red reaction (AU400 Clinical Chemistry System;
Beckman Coulter, Brea, CA, USA) in the Veterinary
Clinical Biochemistry Laboratory of Universitat Autonoma
de Barcelona. Twenty-four-hour urinary albumin was de-
termined using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (Active Motif, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
RNA extraction, reverse transcription, and gene
expression analysis using quantitative real-time
polymerase chain reactions
For molecular studies, the kidney was immediately snap-
frozen in liquid nitrogen and stored at −80 °C. RNA was
extracted from kidneys using the PureLink™ RNA Mini
Kit (Ambion/Thermo Fisher Scientific, Barcelona, Spain)
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according to the manufacturer’s instructions. RNA pur-
ity was analyzed using a NanoDrop ND-1000 V3.3 spec-
trophotometer (NanoDrop Technologies, Wilmington,
DE, USA). RNA was stored at −80 °C. A total of 500 ng
of RNA was used for reverse transcription with a high-
capacity cDNA reverse transcription kit (Applied
Biosystems, Warrington, UK) in accordance with the
manufacturer’s instructions. Tissue expression levels of
the following mediators of immunity and inflammation
were quantified by TaqMan real-time polymerase chain
reaction (ABI Prism® 7700, Applied Biosystems, Spain)
using the comparative Ct method: complement compo-
nent 3 (C3), chemokine (C-C motif ) ligand 2 (CCL2),
CCL5, CD40L, IL-2, IL-6, Toll-like receptor 9 (TLR9),
vascular cell adhesion molecule (VCAM)-1, STAT1,
STAT2, STAT3, STAT4, and STAT5a.
Plasma ELISA for anti-DNA antibodies and serum cytokine
analysis
Levels of anti-DNA antibodies were measured using a
commercially available ELISA kit (Alpha Diagnostic
International, San Antonio, TX, USA) according to the
manufacturer’s instructions. Serum IL-12, TNF-α, IFN-γ,
and monocyte chemoattractant protein (MCP)-1 cyto-
kines were measured using the BD FACSCanto flow cyt-
ometer with a cytometric bead array kit (BD CBA
mouse inflammation kit) according to the manufac-
turer’s instructions (BD Biosciences, San Jose, CA, USA).
Data were acquired and analyzed using BD FCAP soft-
ware and CBA software (BD Biosciences). Serum IL-17
(R&D Systems, Minneapolis, MN, USA) and IFN-α (PBL
Assay Science, Piscataway, NJ, USA) cytokine levels were
quantified using commercially available ELISA kits ac-
cording to the manufacturers’ instructions.
Renal lupus histopathology
For histological analyses, 1- to 2-mm-thick coronal slices
of kidney tissue were fixed in 4 % formaldehyde and em-
bedded in paraffin. For light microscopy, 3- to 4-μm-
thick tissue sections were stained with hematoxylin and
eosin stain and periodic acid-Schiff stain. To determine
the extent of renal damage, two blinded pathologists an-
alyzed all kidney biopsies. Typical glomerular active le-
sions of LN were evaluated: mesangial expansion,
endocapillary proliferation, glomerular deposits, extraca-
pillary proliferation, and interstitial infiltrates, as well as
tubulointerstitial chronic lesions, tubular atrophy, and
interstitial fibrosis. Lesions were graded semiquantita-
tively using a scoring system from 0 to 3 (0 = no
changes, 1 =mild, 2 =moderate, and 3 = severe). Finally,
a total histological score was derived from the sum of all
the described items.
Paraffin-embedded tissue sections were also stained
for CD3 (Abcam, Cambridge, UK). The sections were
blocked and labeled with immunoperoxidase using a
VECTASTAIN ABC kit and an avidin-biotin blocking kit
(Vector Laboratories, Burlingame, CA, USA) according to
the manufacturer’s protocol. Peroxidase-conjugated anti-
body staining was followed by diaminobenzidine substrate
development (Sigma-Aldrich, Madrid, Spain).
Renal immunofluorescence studies
Slices of kidney were fixed in 4 % paraformaldehyde,
embedded in Tissue-Tek® O.C.T. compound (Sakura
Finetek, Alphen aan Den Rijn, the Netherlands), and
stored at −80 °C. Fluorescent staining of 5-μm cryostat
sections was used for confocal microscopy to quantify
glomerular immunoglobulin G (IgG) and C3 deposition.
Sections were directly stained with fluorescein isothio-
cyanate (FITC)-conjugated goat antimouse IgG (Sigma-
Aldrich) and FITC-conjugated C3 (Nordic-MUbio,
Susteren, the Netherlands). For analysis of C3 and IgG
deposition, at least ten glomeruli were visualized and
photographed with an immunofluorescence confocal
microscope (Leica TCS SL spectral confocal microscope;
Leica Microsystems, Mannheim, Germany). Fluorescence
was quantified and normalized with Simulator-Leica con-
focal software (Leica Microsystems) and expressed as
mean fluorescence intensity.
To quantify kidney macrophages, F4/80 immunohisto-
chemistry was used. Briefly, 3-μm-thick kidney tissue sec-
tions embedded in paraffin were incubated with primary
antibody antimouse F4/80 (eBioscience, San Diego, CA,
USA) and incubated overnight at 4 °C. Staining was visual-
ized using a secondary Alexa Fluor 546 dye (Molecular
Probes/Thermo Fisher Scientific, Eugene, OR, USA).
Nuclei were stained blue with DRAQ5 (eBioscience). To
determine macrophage infiltration, at least 15 high-power
fields were counted, and the number of positive cells was
determined and expressed as a mean value.
Statistical analysis
Overall survival was analyzed with the Kaplan-Meier
method. One-way analysis of variance with post hoc tests
were performed to compare proteinuria and anti-dsDNA
antibodies throughout the follow-up, and gene expression
and circulating cytokines were evaluated at the time the
mice were killed. To compare histological data, a nonpara-
metric Kruskal-Wallis test was used. A p value <0.05 was
considered significant. Data are expressed as mean ± SEM.
Results
JAK3 inhibition prolongs survival and ameliorates renal
function
To examine the effects of a JAK3 inhibitor on advanced
LN in mice, we treated 6-month-old NZB/WF1 female
mice with overt renal disease with CP-690,550 and com-
pared this treatment with MMF and CYP as standard
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therapies. Cumulative survival analyzed with the Kaplan-
Meier method was 100 % for the CYP and MMF groups,
85 % for the CP-690,550 group, and 76 % for the control
group at the end of the follow-up.
NZB/WF1 mice at 5 months old had slight to moder-
ate proteinuria and albuminuria, which indicates LN. As
the mice became older, without treatment they typically
had severe disease, as evidenced by a progressive in-
crease in proteinuria and albuminuria levels (Fig. 1).
Twelve weeks of CP-690,550, MMF, and CYP adminis-
tration resulted in significant reduction of urinary pro-
tein and albumin excretion compared with control
animals. At week 36, those parameters were significantly
decreased in all treated animals. Additionally, the results
showed that CP-690,550-treated mice had levels of pro-
teinuria and albuminuria similar to those of mice that
received standard therapies.
JAK3 inhibition affects the production of anti-dsDNA
autoantibodies
Serum levels of anti-dsDNA autoantibodies were deter-
mined at several time points after the beginning of treat-
ment. As shown in Fig. 2, by age 28 weeks, serum titers
of anti-dsDNA autoantibodies progressively increased in
Fig. 1 a Proteinuria and b albuminuria. Twenty-four-hour proteinuria increased progressively in PBS-treated mice (n = 14) to levels of heavy
proteinuria. Treatment with cyclophosphamide (CYP; n = 14), mycophenolate mofetil (MMF; n = 8), and CP-690,550 (CP; n = 8) induced a
progressive reduction of proteinuria almost to physiological levels. *p < 0.05 vs control
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nearly all NZB/WF1 mice. In PBS-treated control ani-
mals, the results showed a severe increase of anti-
dsDNA autoantibodies with disease progression.
All treatment regimens appeared to have some inhibi-
tory effect on autoantibody production. There was a
trend toward anti-dsDNA antibody reduction after week
32. Anti-dsDNA titers in the CYP-, MMF-, and CP-
690,550-treated animals were significantly less than
those in control mice at week 36 (p < 0.05). Note that
while CYP broke the production of anti-dsDNA anti-
bodies from the beginning of treatment, CP-690,550
treatment had a more profound effect and was more
effective at the end of the treatment.
JAK3 inhibition prevents glomerular and tubular lesions
Renal histological analysis was performed on all surviv-
ing animals at the end of the study (Fig. 3). Typical LN
lesions were seen in control mice that developed signifi-
cant glomerulonephritis and interstitial inflammation.
Regarding treatments, the CYP group showed a reduc-
tion in all evaluated lesions compared with vehicle-
treated mice, exhibiting a pronounced reduction in
endocapillary proliferation, glomerular deposits, and
tubular atrophy. In the MMF group, glomerular de-
posits, extracapillary proliferation, and interstitial fibrosis
were absent. Nevertheless, MMF animals showed im-
portant mesangial expansion and interstitial infiltrate
compared with vehicle animals. CP-690,550 treatment
induced a drastic reduction in endocapillary prolifera-
tion, glomerular deposits, and interstitial infiltrate, while
other lesions, such as extracapillary proliferation, tubular
atrophy, and interstitial fibrosis, were completely absent.
Mean histological scores were as follows: CYP = 2.6 ±
0.8, MMF = 1.6 ± 0.5, and CP = 2.6 ± 1.2. These scores
were statistically different with respect to the control
group (control = 8.6 ± 1.1; p < 0.001).
Complement and IgG glomerular deposits are reduced by
JAK3 inhibition
Intrarenal deposits of IgG and complement in the glom-
eruli were significantly diminished in all treated animals
compared with the control group (Fig. 4). IgG glomeru-
lar deposits were lower in the CP group than in the con-
trol and CYP groups. C3 glomerular deposits were also
reduced in all treatment groups, although in this case
CYP treatment was more effective than MMP and CP-
690,550 treatment.
Macrophages and T-cell infiltration in the glomeruli are
hampered by JAK3 inhibition
To better characterize the inflammatory cell infiltration
observed with conventional histology, F4/80 (macro-
phage) and CD3 (T-cell) surface markers were analyzed
(Fig. 5). The number of cells that stained positive for F4/
80 was significantly reduced in all treated groups com-
pared with the control group. As can be seen in the pho-
tomicrographs in Fig. 5, macrophages were localized
mainly around the glomeruli close to the Bowman’s cap-
sules and in the interstitial area.
T-lymphocyte infiltration evidenced by CD3 immuno-
staining showed that, again, all treatments affected kid-
ney CD3 infiltration. Infiltrating CD3+ cells were
localized in the tubule-interstitium space, where den-
dritic cells and other inflammatory cells are commonly
found.
Fig. 2 Anti-double-stranded (anti-dsDNA) antibodies. Anti-dsDNA antibodies increased progressively in PBS-treated control mice. CP-690,550 (CP)
treatment reduced this production more effectively than cyclophosphamide (CYP) or mycophenolate mofetil (MMF) treatment. *p < 0.05
vs control
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JAK3 inhibition modulates renal inflammatory gene
expression
Expression analysis of different inflammatory genes in
the kidney (Table 1) revealed that there was a significant
upregulation in their expression compared with healthy
animals. The JAK-STAT pathway is key in the pathogen-
esis of LN, so vehicle-treated control animals displayed
an elevated expression of STAT genes that signal down-
stream in the cascade of JAK receptors (STAT1, STAT2,
STAT3, STAT4, and STAT5a). All treatments induced a
reduction in expression of these genes, achieving almost
healthy levels, which indicates good inhibition of the
pathway by all the compounds, especially CP-690,550.
C3 gene expression, as a manifestation of local comple-
ment synthesis, was significantly reduced in all treat-
ments. These results paralleled the C3 glomerular
deposits. CCL2 and CCL5 are genes related to the re-
cruitment of several inflammatory cells into inflamma-
tory sites, and they play an important role in the
recruitment of monocytes, T cells, dendritic cells, eosin-
ophils, and so forth. The results showed that all of these
genes were diminished in treated animals. Another gene
that participates in cell adhesion is VCAM. Its expres-
sion was reduced by all treatments, according to the kid-
ney cell infiltration results. The costimulatory pathway
was also affected by CYP, MMF, and CP-690,550
Fig. 3 Renal histopathology. a Cyclophosphamide (CYP), mycophenolate mofetil (MMF), and CP-690,550 (CP) treatment reduced the elementary
histological lesions of lupus nephritis (LN). b Representative photomicrograph of renal histology for each group (×200 original magnification,
hematoxylin and eosin stain). Data are expressed as mean ± SEM. ap < 0.05 vs control
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treatment. CD40L was reduced in all treated animals.
An intense local effect in inflammatory cytokine expres-
sion was observed. IL-2 and IL-6 were significantly re-
duced in all treatment groups. There was no evidence of
activation of TLR4 (data not shown). TLR9, a sensor of
dsDNA, was overexpressed in vehicle-treated animals
and was strongly reduced by all treatments.
JAK3 inhibition decreases proinflammatory systemic
circulating cytokines
To determine whether the different treatments modified
the systemic inflammatory response, we measured serum
levels of some proinflammatory cytokines (Fig. 6). LN in-
duced an increase in the secretion of different pathogenic
proinflammatory cytokines, such as IL-12, IL-17, TNF-α,
MCP-1, IFN-α, and IFN-γ, compared with healthy animals
(data not shown). CYP treatment induced a reduction in
almost all these cytokines. Of note, CYP treatment did not
affect IFN-α circulating levels. MMF treatment appeared
to be less immunomodulatory, considering secretion of
this cytokine. JAK3 inhibition showed a trend toward re-
ducing all the evaluated Th1 cytokines, but it is note-
worthy that there were significant reductions in the
secretion of TNF-α, IFN-α, and IL-17.
Discussion
With recent insight into the pathological role of JAK-
STAT proteins in the inflammatory process, it has
Fig. 4 Immunofluorescence analysis of renal immunoglobulin G (IgG) and complement component 3 (C3) deposits. Deposits of renal C3 (a) and
IgG (b) were quantified with confocal microscopy, and the results were expressed as mean fluorescence intensity (MFI). All treatments reduced
glomerular deposits. c Representative photomicrographs of C3 deposits (×630 original magnification) for each group. d Representative photomicrographs
of IgG deposits (×630 original magnification) for each group. Data are expressed as mean± SEM. *p< 0.05 vs control. CP CP-690,550; CYP cyclophosphamide;
MMF mycophenolate mofetil
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become feasible to target this pathway in order to modu-
late their pathogenic effects. In this study, we have dem-
onstrated that treatment of NZB/WF1 mice, a well-
recognized experimental murine model of autoimmune
nephritis, with the JAK3 inhibitor CP-690,550 resulted
in improved animal survival, delayed the progression of
the disease, and ameliorated renal function, preventing
kidney cell infiltration and complement deposition. We
have also proven that treatment with CP-690,550 re-
duced the severity of typical tubular and glomerular le-
sions and that JAK-STAT inhibition had an impact on
autoantibody formation, as illustrated by a reduction in
circulating anti-dsDNA antibody titers, a hallmark of the
disease. As expected, either renal mRNA expression or
circulating inflammatory cytokine signaling through the
JAK-STAT pathway was diminished.
CYP has been used as a standard treatment for SLE
and LN, but its toxicity and relatively low effectiveness
in preventing disease relapse have made its use less com-
mon; more than 30 % of patients with LN relapse within
3 years after cessation of therapy. In addition to CYP, we
included MMF in our experimental design, which now-
adays is becoming a reference drug for the treatment of
patients with LN [21]. In our present study, we have
proven in an experimental mouse model that both drugs
exert similar potent effects in all the evaluated parame-
ters, as previously reported in patients [21].
The role played by proinflammatory cytokines in the
pathogenesis of LN has been clearly established [22, 23].
One of the promising developments in the last decade has
been the identification of the function of the IL-23/Th17
pathway in autoimmune disease initiation, progression,
Fig. 5 Macrophages and T-cell kidney infiltrate. a Kidney macrophages and b T-cell infiltration were quantified. All treatment clearly reduced renal
infiltration. Representative photomicrographs (×200 original magnification) of (c) macrophage and (d) T-cell infiltration for each group. Data are
expressed as mean ± SEM. ap < 0.05 vs control. CP CP-690,550; CYP cyclophosphamide; MMF mycophenolate mofetil
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and maintenance. Recent studies have demonstrated that
either circulating IL-17 or Th17 cells by themselves were
positively correlated with the Systemic Lupus Erythemato-
sus Disease Activity Index [24]. A strong correlation was
observed in serum levels of IL-17 in patients with SLE,
suggesting that IL-17 may drive activation of diverse
autoimmune pathways. Many of the cytokines involved in
LN and other autoimmune diseases, including IL-17,
signal through receptors associated with JAKs, and CP-
690,550 targets JAK3, which plays a pivotal role in the be-
ginning of the inflammatory cytokine signaling pathway.
In this sense, the present study demonstrates that inhib-
ition of the JAK-STAT pathway is essential in preventing
proinflammatory cytokines from fulfilling their role.
LN is characterized by the presence of circulating
autoantibodies as well as deposition of immune com-
plexes or components in renal tissue [25, 26]. As our re-
sults show, CP-690,550 treatment significantly reduced
the deposition of IgG and C3 in the glomeruli, probably
as a result of the inhibition of circulating autoantibodies,
as reflected by the reduced anti-dsDNA serum levels in
treated animals. Also, our results suggest that CP-
690,550 is more effective than CYP or MMF in the in-
hibition of anti-dsDNA autoantibody formation. In other
studies, researchers have demonstrated the influence of
CP-690,550 in autoantibody formation. Yamamoto et al.
[27] showed that disease activity in patients with
rheumatoid arthritis with insufficient response to metho-
trexate and patients with SLE decreased with CP-
690,550 treatment, and that the elevated titers of both
rheumatoid factor and anti-DNA antibodies became
negative.
A crucial pathological feature of LN is the inflamma-
tory infiltration triggered by tissue immune deposition
[28, 29]. Our results show a prominent infiltration of T
cells and macrophages in renal tissue in vehicle-treated
Table 1 Kidney gene expression
Gene Control CYP MMF CP p Value
C3 4.8 ± 1.6 1.61 ± 0.4a 1.67 ± 0.2a 2.1 ± 0.4a 0.02
CCL2 3.5 ± 0.9 1.35 ± 0.4 2.7 ± 0.9 2 ± 0.6 NS
CCL5 1.4 ± 0.4 0.43 ± 0.1 0.9 ± 0.2 0.9 ± 0.4 NS
CD40L 1.2 ± 0.3 0.4 ± 0.1a,b 0.8 ± 0.2 0.1 ± 0.1a,b 0.0017
IL2 1.3 ± 0.4 0.5 ± 0.2a 0.3 ± 0.1a 0.2 ± 0.1a 0.02
IL6 3.3 ± 1.7 0.3 ± 0.0a 0.9 ± 0.3a 0.5 ± 0.1a 0.03
TLR9 1.5 ± 0.1 0.3 ± 0.1a 0.5 ± 0.1a 0.6 ± 0.1a 0.0001
VCAM1 1.2 ± 0.1 0.8 ± 0.2 0.6 ± 0.1 0.9 ± 0.1 NS
STAT1 2.01 ± 0.2 0.66 ± 0.3a 0.71 ± 0.1a 0.48 ± 0.1a 0.0001
STAT2 1.86 ± 0.1 0.82 ± 0.1a 0.86 ± 0.1a 0.57 ± 0.1a 0.0001
STAT3 2.14 ± 0.4 0.92 ± 0.1a 0.99 ± 0.2 0.98 ± 0.1a 0.016
STAT4 2.23 ± 0.3 0.42 ± 0.1a 0.51 ± 0.1a 0.21 ± 0.1a 0.0001
STAT5a 1.42 ± 0.3 0.64 ± 0.1a 0.59 ± 0.1a 0.62 ± 0.1a 0.021
Abbreviations: C3, complement component 3, CCL chemokine (C-C motif)
ligand, CP CP-690,550, CYP cyclophosphamide, IL interleukin, MMF mycophenolate
mofetil, NS not significant, STAT signal transducer and activator of transcription,
TLR Toll-like receptor, VCAM1 vascular cell adhesion molecule 1
Data presented are fold changes in 18S ribosomal RNA, house keeping gene
for random target polymerase chain reaction
aCompared with control
bCompared with MMF
Fig. 6 Systemic circulating inflammatory cytokines. Lupus nephritis promoted overexpression of proinflammatory cytokines in serum. Treatment
with cyclophosphamide (CYP), mycophenolate mofetil (MMF), and CP-690,550 (CP) reduced their levels. Data are expressed as mean ± SEM. *p <
0.05 vs control. IFN interferon, IL interleukin, MCP monocyte chemoattractant protein, TNF tumor necrosis factor
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animals. Also, there was an increase in serum MCP-1, as
well as prominent renal gene expression of regulated on
activation, normal T cell expressed and secreted
(RANTES) and MCP-1, which are potent chemoattrac-
tants for monocytes and T cells [30]. CP-690,550 treat-
ment significantly reduced both T-cell and macrophage
kidney infiltration, with a slight reduction in serum MCP-
1 but a greater reduction in MCP-1 and RANTES renal
gene expression. Finally, the renal reduction of all STAT
components, indicating local inhibition of the downstream
JAK-STAT pathway, may participate in the modulation of
the renal inflammatory microenvironment.
Some other authors have demonstrated that treatment
of lupus-prone mice with JAK2 inhibitors led to disease
prevention or improvement. Wang et al. showed that
JAK2 inhibition in MRL/lpr mice led to a decrease in
proteinuria, serum levels of dsDNA, renal cell infiltra-
tion, and deposition of IgG and C3 in the kidney [31].
Lu et al. used another JAK2 inhibitor in NZB/WF1 mice
and showed improved survival, reduced proteinuria, and
diminished dsDNA antibodies and spleen plasma cells;
additionally, several cytokines were downregulated with
treatment [32]. However, all of these studies were
focused on the inhibition of JAK2; JAK2 specifically
mediates cytokine signaling for red blood cells and plate-
lets, and its inhibition causes anemia and low platelets
[33, 34]. The results of our present study clearly show
that selective inhibition of JAK3 is ready to use as a new
treatment for LN in clinical practice, given its profile
and good tolerability in autoimmune diseases.
Apart from conventional inflammatory cytokines, gene
expression analysis revealed the reduction of other medi-
ators in renal tissue. TLR9 was, as expected, increased in
control animals, and it was significantly reduced by all
treatments. We also observed that the JAK-STAT path-
way affected CD40L expression; blocking this pathway
induced a severe and significant reduction of its expres-
sion, thereby affecting CD40-CD40L interaction. It is
well known that this dyad plays a central role in the de-
velopment of immune-mediated inflammatory disease
processes [35, 36], and we previously showed that block-
ing this pathway was also effective in the prevention of
LN [37].
Finally, in our present study, we observed a dramatic
drop in circulating levels of IL-12, IFN-α, and TNF-α in
animals that received CP-690,550 treatment. The influ-
ence of JAK3 inhibition on inflammatory cytokines was
also observed by Ghoreschi et al. [20], who reported a
rapid improvement of the disease with CP-690,550 in a
model of established arthritis, with inhibition of inflam-
matory mediators such as IFN-γ, IL-6, IL-12, and IL-23
in joint tissue. Further, Rosengren et al. showed that CP-
690,550 decreased TNF-induced chemokine expression
in fibroblasts from patients with rheumatoid arthritis
[38]. No previous information has been reported regard-
ing the effects of JAK inhibitors on IL-17 in experimen-
tal LN, but in our present study CP-690,550 treatment
resulted in a consistent reduction of circulating IL-17
levels. In fact, the STAT3 transcription factor is essential
for the differentiation of Th17 cells [7], and it is effect-
ively inhibited by CP-690,550. As circulating IL-17A has
been associated with immune complex deposition and
complement activation in kidneys in a mouse model of
lupus [8], it is quite likely that reduction of IL-17 in the
bloodstream has a systemic mechanism that participates
in the reduction of renal inflammation.
Conclusions
Our data strongly support the idea that the JAK-STAT
pathway is implicated in the progression of renal inflam-
mation in NZB/WF1 mice. Our results also provide evi-
dence of the potential therapeutic effects of targeting
this pathway with CP-690,550 as part of a robust strat-
egy of immune disruption in autoimmune LN disease,
particularly when treatment is initiated during the early
phases of the disease. This has the potential to become a
powerful new therapeutic tool in the treatment of LN
and other autoimmune diseases.
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